KR20240163080A - 인터페론 관련 질환의 치료에서 hpk1 억제제의 응용 - Google Patents

인터페론 관련 질환의 치료에서 hpk1 억제제의 응용 Download PDF

Info

Publication number
KR20240163080A
KR20240163080A KR1020247031682A KR20247031682A KR20240163080A KR 20240163080 A KR20240163080 A KR 20240163080A KR 1020247031682 A KR1020247031682 A KR 1020247031682A KR 20247031682 A KR20247031682 A KR 20247031682A KR 20240163080 A KR20240163080 A KR 20240163080A
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
virus
alkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247031682A
Other languages
English (en)
Korean (ko)
Inventor
웬주안 웨이
홍 펭
타오 후앙
시안징 후
Original Assignee
아스클리피온 파마수티컬 씨오., 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스클리피온 파마수티컬 씨오., 엘티디 filed Critical 아스클리피온 파마수티컬 씨오., 엘티디
Publication of KR20240163080A publication Critical patent/KR20240163080A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247031682A 2022-02-23 2023-02-23 인터페론 관련 질환의 치료에서 hpk1 억제제의 응용 Pending KR20240163080A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210168693.X 2022-02-23
CN202210168693.XA CN116672450A (zh) 2022-02-23 2022-02-23 Hpk1抑制剂在治疗干扰素相关疾病中的应用
PCT/IB2023/051675 WO2023161844A1 (zh) 2022-02-23 2023-02-23 Hpk1抑制剂在治疗干扰素相关疾病中的应用

Publications (1)

Publication Number Publication Date
KR20240163080A true KR20240163080A (ko) 2024-11-18

Family

ID=87764942

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247031682A Pending KR20240163080A (ko) 2022-02-23 2023-02-23 인터페론 관련 질환의 치료에서 hpk1 억제제의 응용

Country Status (8)

Country Link
US (1) US20250161319A1 (https=)
EP (1) EP4483880A4 (https=)
JP (1) JP2025508495A (https=)
KR (1) KR20240163080A (https=)
CN (1) CN116672450A (https=)
AU (1) AU2023226510A1 (https=)
CA (1) CA3244921A1 (https=)
WO (1) WO2023161844A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116514728A (zh) * 2022-01-28 2023-08-01 赛诺哈勃药业（成都）有限公司 一种喹唑啉衍生物及其用途
WO2025228828A1 (en) * 2024-04-29 2025-11-06 Merck Patent Gmbh Carboxamide compounds for the treatment and prevention of viral diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
WO2015083833A1 (ja) * 2013-12-06 2015-06-11 カルナバイオサイエンス株式会社 新規キナゾリン誘導体
EP3601259B1 (en) * 2017-03-30 2022-02-23 F. Hoffmann-La Roche AG Isoquinolines as inhibitors of hpk1
TW202019905A (zh) * 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
WO2020255022A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors
TW202116753A (zh) * 2019-07-11 2021-05-01 大陸商南京征祥醫藥有限公司 以噌啉作為hpk1的抑制劑
KR20210143131A (ko) * 2020-05-19 2021-11-26 한국화학연구원 2-아미노퀴나졸린 유도체 및 이를 포함하는 항바이러스용 조성물
CN113797202B (zh) * 2020-06-16 2024-06-28 珠海宇繁生物科技有限责任公司 Hpk1激酶抑制剂在预防和/或治疗动物的病原体感染中的应用
CN114315798B (zh) * 2020-09-29 2025-03-25 安思科(苏州)医药科技有限公司 喹唑啉类化合物及其药物组合物

Also Published As

Publication number Publication date
CN116672450A (zh) 2023-09-01
WO2023161844A1 (zh) 2023-08-31
JP2025508495A (ja) 2025-03-26
CA3244921A1 (en) 2025-06-13
EP4483880A1 (en) 2025-01-01
EP4483880A4 (en) 2026-03-11
AU2023226510A1 (en) 2024-10-10
US20250161319A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
CA3214900A1 (en) Carboxamide pyrolopyrazine and pyridine compounds useful as inhibitors of myt1 and use thereof in the treatment of cancer
CN103384670B (zh) 取代的咪唑并[1,2-b]哒嗪
TW202128691A (zh) Ｋｒａｓ 突變蛋白抑制劑
CN118043330A (zh) Kras g12d抑制剂化合物及其制备方法和应用
AU2019202922A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
KR20250052473A (ko) (s)-7-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)-4,5,6,7-테트라-하이드로피라졸로[1,5-a] 피리미딘-3-카르복스아미드의 제조 및 그 용도
US20230113478A1 (en) Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof
KR102038401B1 (ko) 키나아제 억제제의 제조 및 응용
KR20240163080A (ko) 인터페론 관련 질환의 치료에서 hpk1 억제제의 응용
CN116947764B (zh) 一种嘧啶胺类nuak抑制剂及其制备方法和用途
KR20200035720A (ko) 3-아자바이사이클로[3,1,1]헵탄 유도체 및 이를 포함하는 약제학적 조성물
US12344596B2 (en) Solid forms of (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof
CN105218548A (zh) 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途
US11858938B2 (en) Imidazo-fused heterocycles and uses thereof
CN111763215A (zh) 一种具有含氮杂环结构的化合物及其制备方法和用途
CN113416181A (zh) 喹唑啉类衍生物及其用途
CN111393447A (zh) 一种嘧啶并吡唑类化合物、其制备方法及应用
WO2023030335A1 (zh) 作为tyk2/jak1假激酶结构域抑制剂的化合物及合成和使用方法
TWI634114B (zh) 作為激酶抑制劑之呋喃酮化合物
CN112250666A (zh) 取代的嘧啶类化合物及其用途
WO2019233366A1 (zh) 选择性a 2a受体拮抗剂
CN119462649A (zh) 酞嗪酮类化合物及其制备方法、药物组合物和应用
CN115716829A (zh) 一种喹啉并咪唑酮联氘代吡唑类化合物及其应用
CN113372345A (zh) 氘代杂环类激酶抑制剂
WO2002098397A2 (en) Therapeutic compositions for modulating the immune response in a mammal and use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240923

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application